ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS - this result from @AnavexLifeSci

in Alzheimer’s bodes well for Anavex 2-73 in Parkinson’s

SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE

anavex.com/post/anavex-2-73...

twitter.com/InnovationFixer...

[LeharLover62]

ANAVEX®2-73 demonstrated visible improvement in patients with Alzheimer’s disease. Patients treated with ANAVEX®2-73 were 84% more likely, to have improved cognition by ADAS-Cog score change of -0.50 points or better from baseline to end of treatment than patients on placebo, “

Thank you for sharing. I’ve really been waiting for this study as they seem very promising. They seem to also have a very high safety profile. All my fingers and toes are crossed cause hubby really needs a new med.

I’m wondering because their website shows the PDD drug as also in Phase 3 but there doesn’t seem to be any news about it….wait I found this in a press release from last month:

“Prior to the completion of the larger Phase 2b/3 study ANAVEX®2-73-AD-004 (NCT03790709) for the treatment of Early Alzheimer’s Disease, using precision medicine included SIGMAR1 biomarker of response, ANAVEX®2-73 (blarcamesine) successfully completed a randomized, double-blind, multicenter, placebo-controlled Phase 2 in Parkinson’s disease dementia and a Phase 2a clinical trial for Alzheimer’s disease.”